DRUG CARDS A-list Paramedic rev0807 117KB Jan 14 2015
... EMT-PARAMEDIC –Drug Cards Pharmacology Please note Many drugs have nausea, vomiting, dizziness as side effects All drugs are metabolized/eliminated by the liver and kidneys and should be given cautiously to patients with diseases in these body systems You should never give any drug to a patien ...
... EMT-PARAMEDIC –Drug Cards Pharmacology Please note Many drugs have nausea, vomiting, dizziness as side effects All drugs are metabolized/eliminated by the liver and kidneys and should be given cautiously to patients with diseases in these body systems You should never give any drug to a patien ...
Hallucinogens - People Server at UNCW
... Spontaneous recurrence of trip after period of normalcy • can occur after long periods of abstinence • more common after multiple high dose use • prolonged afterimages for days and weeks after – mechanism unknown ...
... Spontaneous recurrence of trip after period of normalcy • can occur after long periods of abstinence • more common after multiple high dose use • prolonged afterimages for days and weeks after – mechanism unknown ...
Multisource drug product
... substance in the same dosage form and is marketed by more than one pharmaceutical manufacturer. Single-source drug products are drug products for which the patent has not yet expired or has certain exclusivities so that only one manufacturer can make it. Bioavailability. Bioavailability means the ra ...
... substance in the same dosage form and is marketed by more than one pharmaceutical manufacturer. Single-source drug products are drug products for which the patent has not yet expired or has certain exclusivities so that only one manufacturer can make it. Bioavailability. Bioavailability means the ra ...
NSAIDs: Friend or Foe
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
here - American Epilepsy Society
... interval, or with severe cardiac disease such as myocardial ischemia or heart failure, or structural heart disease. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state maintenance dose, is recommended. In addition, these patients should be closely ...
... interval, or with severe cardiac disease such as myocardial ischemia or heart failure, or structural heart disease. In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state maintenance dose, is recommended. In addition, these patients should be closely ...
NSAIDs: Friend or Foe
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
... may be used in those with a history of ulceration Always consider prescribing gastric protection in form of PPI for those requiring long-term tNSAIDs OR coxibs NICE judged that it is cost-effective to add generic PPI to tNSAIDs or coxibs used as treatment for rheumatoid or osteoarthritis NICE advise ...
Product Monograph - Ask Novartis Pharma
... Renal impairment: After oral LIORESAL* dosing, severe neurological outcomes including clinical manifestations of toxic encephalopathy (e.g. somnolence, depressed level of consciousness and coma) have been reported in patients with renal impairment. Caution should be exercised while administering LIO ...
... Renal impairment: After oral LIORESAL* dosing, severe neurological outcomes including clinical manifestations of toxic encephalopathy (e.g. somnolence, depressed level of consciousness and coma) have been reported in patients with renal impairment. Caution should be exercised while administering LIO ...
Amiodarone Shared Care Guideline - Interface Pharmacist Network
... Statins: Concurrent use with CYP3A4 metabolised statin therapy may increase the risk of muscular toxicity. If statin therapy is required, use of reduced dose atorvastatin or a statin not metabolised by CYP3A4 is preferred. Concurrent use with simvastatin is best avoided, but if co-prescribed, the ma ...
... Statins: Concurrent use with CYP3A4 metabolised statin therapy may increase the risk of muscular toxicity. If statin therapy is required, use of reduced dose atorvastatin or a statin not metabolised by CYP3A4 is preferred. Concurrent use with simvastatin is best avoided, but if co-prescribed, the ma ...
A case for psilocybin
... That the studies replicated one another is a source of confidence in their findings. However, there were also informative differences between the studies. The group at JHU led by Griffiths et al. investigated the effects of a very low dose (1–3 mg/70 kg, placebo-like) versus high dose (22 mg/70 kg) ...
... That the studies replicated one another is a source of confidence in their findings. However, there were also informative differences between the studies. The group at JHU led by Griffiths et al. investigated the effects of a very low dose (1–3 mg/70 kg, placebo-like) versus high dose (22 mg/70 kg) ...
IV Infusion Drugs ACLS Drugs
... 6 mg rapid IVP followed by NS bolus of 20 ml Repeat w/12 mg after 1-2 min if needed May repeat w/12 mg after 1-2 min if needed ...
... 6 mg rapid IVP followed by NS bolus of 20 ml Repeat w/12 mg after 1-2 min if needed May repeat w/12 mg after 1-2 min if needed ...
IN VITRO LORNOXICAM USING NATURAL PERMEATION ENHANCERS Original Article
... absorbed in GIT, bioavailability is 90–92% and it inhibits the prostaglandin synthesis. LX was chosen as a model drug for these studies, it possess near ideal characteristic, that a drug must have in formulating a drug delivery system such as low molecular weight, effective in low plasma concentrati ...
... absorbed in GIT, bioavailability is 90–92% and it inhibits the prostaglandin synthesis. LX was chosen as a model drug for these studies, it possess near ideal characteristic, that a drug must have in formulating a drug delivery system such as low molecular weight, effective in low plasma concentrati ...
Revised: November 2012 AN: 00974/2012 SUMMARY OF
... time, with associated monitoring of serum Phenobarbital levels. The Phenobarbital serum concentration may be checked after steady state has been achieved, and if it is less than 15µg/ml the dose may be adjusted accordingly. If seizures recur the dose may be raised up to a maximum serum concentration ...
... time, with associated monitoring of serum Phenobarbital levels. The Phenobarbital serum concentration may be checked after steady state has been achieved, and if it is less than 15µg/ml the dose may be adjusted accordingly. If seizures recur the dose may be raised up to a maximum serum concentration ...
Pharmacology
... •How the drug is distributed in the body and how it is eliminated •Blood, urine and organs •Safety data of different time courses •Short and long-term administration •Animals on long-term administration are monitored for the development of cancer ...
... •How the drug is distributed in the body and how it is eliminated •Blood, urine and organs •Safety data of different time courses •Short and long-term administration •Animals on long-term administration are monitored for the development of cancer ...
Ganeden Biotech Clinical Summaries - Nutra
... the strain in the presence of lactose and fructose was markedly lower (56-59%) than in the absence of the sugars. The amount of digested milk protein available for absorption was somewhat higher (+0.2 g) when GanedenBC30 was added to the milk. When GanedenBC30 was tested with lactose or fructose add ...
... the strain in the presence of lactose and fructose was markedly lower (56-59%) than in the absence of the sugars. The amount of digested milk protein available for absorption was somewhat higher (+0.2 g) when GanedenBC30 was added to the milk. When GanedenBC30 was tested with lactose or fructose add ...
Policy XI.B
... b. Charging for Investigational Drugs for Treatment Use under Expanded Access: The FDA permits charging for the drug, agent, or biologic under expanded access if certain conditions are met. Therefore, the IRB Committee should pay particular attention to expanded access submissions in which the subje ...
... b. Charging for Investigational Drugs for Treatment Use under Expanded Access: The FDA permits charging for the drug, agent, or biologic under expanded access if certain conditions are met. Therefore, the IRB Committee should pay particular attention to expanded access submissions in which the subje ...
PDF
... for many years. Recently, immunoglobulin (Ig) administration via subcutaneous route has become popular. Subcutaneously administered immunoglobulin (SCIG) provides more stable serum Ig levels and has lower incidence of systemic adverse effects than intravenous route. This method increases quality of ...
... for many years. Recently, immunoglobulin (Ig) administration via subcutaneous route has become popular. Subcutaneously administered immunoglobulin (SCIG) provides more stable serum Ig levels and has lower incidence of systemic adverse effects than intravenous route. This method increases quality of ...
STARTing and STOPPing Medications in the Elderly
... resulting in patient harm.6 Also, there are medications that should be avoided in the elderly but that are not included in these lists. Drug interactions, duplications, and underprescribing are not addressed. And the lists are poorly organized. 7 The STOPP (Screening Tool of Older Persons’ potential ...
... resulting in patient harm.6 Also, there are medications that should be avoided in the elderly but that are not included in these lists. Drug interactions, duplications, and underprescribing are not addressed. And the lists are poorly organized. 7 The STOPP (Screening Tool of Older Persons’ potential ...
Halcion: Yesterday, Today, and Tomorrow
... Phenobarbital (and other barbiturates) Modafinil (Provigil) St. John’s wort (hypericum) Cigarette smoke (aryl hydrocarbons) ...
... Phenobarbital (and other barbiturates) Modafinil (Provigil) St. John’s wort (hypericum) Cigarette smoke (aryl hydrocarbons) ...
Angiotensin-Receptor Blockade in Acute Myocardial Infarction — A
... Evaluation of Losartan in the Elderly II trial, the results similarly favored captopril.8 In contrast, in two recently reported clinical trials in which the investigators were allowed to increase the dose of losartan gradually to 100 mg per day, there was a significant reduction in the incidence of ...
... Evaluation of Losartan in the Elderly II trial, the results similarly favored captopril.8 In contrast, in two recently reported clinical trials in which the investigators were allowed to increase the dose of losartan gradually to 100 mg per day, there was a significant reduction in the incidence of ...
Reappraisal of the European guidelines on hypertension management
... reasonable to recommend that, in patients with grade 1 hypertension (systolic BP ≥140–159 or diastolic BP ≥90–94 mmHg) at low and mod‑ erate risk, drug therapy should be started, if BP is 140/90 mmHg or higher after a suitable pe‑ riod of time with appropriate lifestyle changes, with the goal to bri ...
... reasonable to recommend that, in patients with grade 1 hypertension (systolic BP ≥140–159 or diastolic BP ≥90–94 mmHg) at low and mod‑ erate risk, drug therapy should be started, if BP is 140/90 mmHg or higher after a suitable pe‑ riod of time with appropriate lifestyle changes, with the goal to bri ...
DUEXIS® (ibuprofen 800mg/famotidine 26.6mg) oral tablet
... ingredient is involved, use of same or a chemically similar agent places the individual at risk for harm when the same or chemically similar agent is used. The subsequent reaction may be the same as the original reaction or a more exaggerated response may be seen, potentially placing the individual ...
... ingredient is involved, use of same or a chemically similar agent places the individual at risk for harm when the same or chemically similar agent is used. The subsequent reaction may be the same as the original reaction or a more exaggerated response may be seen, potentially placing the individual ...
- Boehringer Ingelheim (Canada)
... Patients with Congestive Heart Failure: A limited number of patients with history of congestive heart failure participated in clinical studies with TRAJENTA. In clinical trials, patients with a clinically significant history of cardiac disease or presence of active cardiac disease within 6 months we ...
... Patients with Congestive Heart Failure: A limited number of patients with history of congestive heart failure participated in clinical studies with TRAJENTA. In clinical trials, patients with a clinically significant history of cardiac disease or presence of active cardiac disease within 6 months we ...
VICH GL36(R): Studies to evaluate the safety of residues of
... Each MIC test of a pure culture of a relevant isolate provides data for a single strain of a species. Other in vitro test systems provide information for hundreds of bacterial species (>108 bacterial cells/g) for each fecal inoculum. Each inoculum can be tested in replicate to determine treatment ef ...
... Each MIC test of a pure culture of a relevant isolate provides data for a single strain of a species. Other in vitro test systems provide information for hundreds of bacterial species (>108 bacterial cells/g) for each fecal inoculum. Each inoculum can be tested in replicate to determine treatment ef ...